Coverage from the 61st Annual ASH Meeting & Exposition: Focus on Acute Myeloid Leukemia
The 61st ASH Annual Meeting and Exposition will be held in Orlando, Fla., Dec. 7-10, 2019. Attendees will have access to thousands of scientific abstracts highlighting cutting-edge research in hematology. This conference is an opportunity to enhance your practice through educational programs while networking with leaders in the field. Check out highlights from the upcoming conferences to help you make the most of your time at ASH.
Lead investigators from the U.S. and French phase Ib/II clinical trials of APR-246 and azacitidine (AZA) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), presented positive data at the 2019 ASH Annual Meeting.
Researchers found that the combination of OPB-111077 and venetoclax in acute myeloid leukemia cells caused decreased proliferation and increased apoptosis rates to a greater degree than exposure to single agent OPB-111077 or venetoclax.
Updated results from a phase I/II dose-expansion study of flotetuzumab, an investigational, bispecific CD123 x CD3 DART molecule in patients with primary induction failure and early relapsed acute myeloid leukemia were presented in an oral session at the 2019 ASH Annual Meeting.
There has been considerable interest recently in the expression of cell surface proteins in acute myeloid leukemia (AML), primarily as a result of their potential for being targeted therapeutically, as well as their prognostic implications in patient disease. In AML, one particular surface-bound protein of interest is the receptor tyrosine kinase CD117, also referred to as c-KIT.